Slide 1: Fourth Quarter and Full Year 2023 Financial Results
Exhibit 99.2 February 28, 2024 Fourth Quarter and Full Year 2023 Financial Results
Slide 2: Welcome and Participants
Welcome and Participants Dr. Jeffrey Graves President & Chief Executive Officer Jeffrey Creech Executive Vice President & Chief Financial Officer Andrew Johnson Executive Vice President, Chief Corporate Development Officer & Chief Legal Officer Mick McCloskey Vice President, Treasury & Investor Rela
Slide 3: Forward Looking Statements
Forward Looking Statements Certain statements made in this presentation that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncert
Slide 4: Dr. Jeffrey Graves, President & Chief Executive Officer
Dr. Jeffrey Graves President & Chief Executive Officer 4
Slide 5: Why Invest?
t e k r a M g n i t n Why Invest? $80B+ Why choose additive manufacturing (AM)? 1 2029 ✓ Design Flexibility ✓ Mass Customization ✓ Low Volume Parts ✓ Supply Chain Flexibility ~$15B 1 2021 Why 3D Systems? ✓ Unmatched combination of portfolio and scale ~21% ➢ Broadest range of technologies (metals, po
Slide 6: 2023 in Review
2023 in Review • Challenging 2023 for AM industry ▪ Significant FY’23 headwind in our dental orthodontics business, ~39% decline vs. FY’22 ▪ Challenging macroeconomic and uncertain geopolitical environment created headwinds for remaining businesses, particularly printer sales • Strong gross margin i
Slide 7: Right-Sizing Cost, Preserving Mission-Critical Growth
Right-Sizing Cost, Preserving Mission-Critical Growth Strong balance sheet supports ability to better Reducing costs to navigate current Implemented restructuring establish sustainable environment – healthy initiative in response to profitability but not cash reserves and current revenue compromisin
Slide 8: End-to-End Solutions to Address Orthopedic Device Market
End-to-End Solutions to Address Orthopedic Device Market Applications throughout the human body CMF (Cranio-Maxillofacial) Spine Surgical Planning + Guides + Highest adoption of DMP 350 Implants technology for Titanium spine cages (~$2B) (~$10B) Targeted for Future Growth Hip & Knee Foot & Ankle DMP
Slide 9: Bright Future Ahead for Personalized Healthcare
Bright Future Ahead for Option 2 (2 slides) – I prefer the two slide Personalized Healthcare option. This image is very grainy. Where Personalized Healthcare delivered was this pulled from? double-digit full year revenue growth in 2023 Investing heavily to increase coverage into global markets as cr
Slide 10: Jetted Dentures
Jetted Dentures Two unique materials Industry First Solution Enable production of superior monolithic dentures, combining beautiful aesthetics with outstanding performance, yielding a market-leading denture solution “The capabilities presented by the new jetted denture solution are unmatched in the
Slide 11: Industrial Metal Printing Innovation
Industrial Metal Printing Innovation Semiconductor Capital Equipment, Shipbuilding, Aerospace & Defense • AM generating greater momentum in semiconductors, shipbuilding, aerospace and defense • Lower technical barriers to entry with proven solutions for many materials and applications • Parts consol
Slide 12: Building Momentum on a Historic Technology Roadmap
Building Momentum on a Historic Technology Roadmap ➢ Delivered 9 new products during 4Q’23 ➢ 5 new materials ➢ 3 printer upgrades ➢ 1 key accessory ➢ Recently shipped our first MJP300W and production ramp is ongoing ➢ Completed validation testing on SLS300, ramping production and shipments by 1H’24
Slide 13: Regenerative Medicine Initiative
Regenerative Medicine Initiative Human Organs Regenerative Tissue Program Drug Development Vascularized Breast Tissue Scaffold for Implantation & Cellularization Bioprinted “Organ-on-a-chip” Most Complex Object can accurately replicate organ-specific drug response in pre- Ever 3D Printed clinical dr
Slide 14: Systemic Bio
Systemic Bio Simplifying the challenges in drug discovery 9 in 10 $2.6B 12 YEARS in development 1 2 DRUGS FAIL CLINICAL TRIALS 1 PER DRUG APPROVED FOR FDA APPROVAL • Wholly-owned subsidiary formed in 2022 • h-VIOS , proprietary organ- on-a-chip platform allows pharma companies to test their drug on
Slide 15: 2024 Expectations
2024 Expectations ✓ Expect relatively flat FY’24 revenues given continued macro softness ✓ In-sourcing and restructuring initiatives provide a strong foundation for margins today…expect continued benefit going forward ✓ Expect breakeven or better Adj. EBTIDA in flat top-line environment 15
Slide 16: Jeffrey Creech, Chief Financial Officer
Jeffrey Creech Chief Financial Officer 16
Slide 17: Full Year Revenue Summary
Full Year Revenue Summary ($ in millions) ISG HSG Consolidated $261 $277 $275 $538 $213 $488 FY’22 FY’23 FY’22 FY’23 FY’22 FY’23 • HSG declined ~18% YoY driven by • ISG revenues declined ~1% YoY • YoY revenue declined ~9% primarily headwind in dental orthodontics driven by headwinds in dental largel
Slide 18: Q4 Revenue Summary
Q4 Revenue Summary ($ in millions) ISG HSG Consolidated $133 $72 $61 $115 $64 $51 Q4’22 Q4’23 Q4’22 Q4’23 Q4’22 Q4’23 • HSG declined ~16% YoY primarily • ISG revenues declined ~12% YoY, • YoY revenue declined ~14% due to decline in dental orthodontics primarily driven by headwinds in primarily drive
Slide 19: Gross Profit Margin (Non-GAAP)
Gross Profit Margin (Non-GAAP) Full Year Compare Fourth Quarter Compare +100 bps +130 bps Full Year Drivers 41.9% 41.1% 40.9% • Continued execution of cost 39.8% optimization efforts & favorable mix Fourth Quarter Drivers • Predominantly favorable mix FY'22 FY'23 Q4'22 Q4'23 19 See Appendix for a r
Slide 20: Earnings (Non-GAAP)
Earnings (Non-GAAP) ($ in millions, except per share amounts) FY’22 FY’23 Change YoY YoY decline driven by lower revenues in Adj. EBITDA ($5.8) ($24.5) ($18.7) addition to: • Investments in Regenerative Medicine for future Non-GAAP growth Diluted loss ($0.23) ($0.26) ($0.03) • Higher than normal OpE
Slide 21: Strong Balance Sheet
Strong Balance Sheet • Ended the quarter with $331.5 million of cash • Invested cash throughout FY’23 - working capital (e.g. in- sourcing manufacturing), acquisitions and other investments (Wematter, Theradapative) and CapEx for growth programs • Opportunistically repurchased ~$135 million of 2026
Slide 22: 2024 Outlook
2024 Outlook Additional Commentary Full Year 2024 Guidance • Expect current macroeconomic and uncertain geopolitical environment to continue impacting $475 – $505 million Revenue top-line • Mid-point of revenue essentially flat YoY, with Non-GAAP seasonally soft start for Q1’24, down QoQ & YoY 42% –
Slide 23: Q&A Session
Q&A Session 1-201-689-8345 23
Slide 24: Thank You
Thank You Find out more at: www.3dsystems.com 24
Slide 25: Appendix
Appendix ©2022 3D Systems, Inc. | All Rights Reserved.
Slide 26: Presentation of Information
Presentation of Information 3D Systems reports its financial results in accordance with GAAP. Management also reviews and reports certain non-GAAP measures, including: non-GAAP revenue excluding divestitures and on a constant currency basis (sometimes referred to as excluding divestitures and FX eff
Slide 27: Constant Currency Revenue
Appendix 3D Systems Corporation ‘Three Months Ended December 31, 2023 and 2022. Constant Currency Revenue stant Currency in howsands) nina 3 ed Indl Soins 1196 33)% Toul sn 160 a7) (© To musta the analy of he Company's revenue tenth, the Company ented temper of reign exchange cu Jearoer Yea teense o
Slide 28: Reconciliation of Gross Profit and Gross Profit Margin
Appendi _3D Systems Corporation ‘Unaudited Reconciliations of GAAP to Non-GAAP M pecaeesernetnterad tiperiymniory Gross Profit and Gross Profit Margin ® (on orants) ona xyes Cot of es 2 Resuctng expense iced i Cost of 1407 - NowGAAr 7 om An i yo et et (in borsends) Amorizato expense inched in Cost o
Slide 29: Net Loss to Adjusted EBITDA
Appendix 3D Systems Corporation Three and 2023 and 2022 Net Loss to Adjusted EBITDA ® (Gn honsands) 2033 2022 2033 2022 ‘Net oss attributable fo 3D Systems Corporation s S$ Gmasy § az7m) nest income, net am) 4696) Cen) (Benefit) provision for income taxes 26 240 Depreciation expense 5656 236 21,096
Slide 30: Non-GAAP Diluted Loss per Share
Unaudited Non-GAAP Diluted Loss per Share in dottars) Diluted loss per share tion expense Stock-based compensation expense Acquisition and divestiture-related expense Appendix sD s stems Corporat tion Ree AAP to Non-GAAP Measures wee and Tw -_ ‘Stowthe nan December 31, 2023 and 2022 2023 2022 2023 2